Gallacher Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$412K Sell
5,264
-3,350
-39% -$228K 0.23% 145
2026
Q1
$557K Buy
8,614
+2,167
+34% +$153K 0.21% 139
2025
Q4
$434K Sell
6,447
-2,659
-29% -$179K 0.17% 174
2025
Q3
$668K Buy
9,106
+3,059
+51% +$203K 0.26% 114
2025
Q2
$315K Sell
6,047
-1,746
-22% -$99.4K 0.15% 203
2025
Q1
$497K Buy
7,793
+1,267
+19% +$73.6K 0.24% 108
2024
Q4
$312K Buy
6,526
+2,291
+54% +$117K 0.15% 186
2024
Q3
$242K Sell
4,235
-2,931
-41% -$168K 0.11% 236
2024
Q2
$375K Sell
7,166
-2,078
-22% -$91.1K 0.2% 148
2024
Q1
$376K Sell
9,244
-2,159
-19% -$80.9K 0.19% 141
2023
Q4
$421K Buy
11,403
+5,245
+85% +$198K 0.24% 97
2023
Q3
$235K Buy
+6,158
New +$252K 0.15% 192

Other funds holding HALO

Gallacher Capital Management's HALO Position: Q2 2026 in Review

Gallacher Capital Management reduced its Halozyme (HALO) stake by 39% in Q2 2026, selling an estimated $228K and leaving 5,264 shares worth $412K. The position accounts for 0.23% of the portfolio, ranked #145.

Gallacher Capital Management first reported a position in HALO in Q3 2023 and has held it in 12 quarters since. The position peaked at $668K in Q3 2025. 135 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Gallacher Capital Management held 5,264 shares of Halozyme worth $412K as of Q2 2026.
  • Gallacher Capital Management sold 3,350 Halozyme shares in Q2 2026, an estimated $228K.
  • Halozyme made up 0.23% of Gallacher Capital Management's portfolio in Q2 2026, its #145 holding.
  • Gallacher Capital Management first reported a position in Halozyme in Q3 2023 and has held it in 12 quarters since.
  • Gallacher Capital Management's Halozyme position peaked at $668K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Gallacher Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.